Myeloperoxidase and its contributory role in inflammatory vascular disease

Pharmacology and Therapeutics

Volumn 111, Issue 1, 2006, Pages 16-26

  Lau, Denise ^a   Baldus, Stephan ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; FIBRONECTIN; HEMOPROTEIN; HYPOCHLOROUS ACID; LIPOPROTEIN; MATRIX METALLOPROTEINASE; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; NITRIC OXIDE; TYROSINE;

ATHEROSCLEROSIS; BLOOD VESSEL WALL; CATALYSIS; DISEASE COURSE; HOMEOSTASIS; HOST RESISTANCE; HUMAN; INFLAMMATORY DISEASE; KNOCKOUT MOUSE; MACROPHAGE; NEUTROPHIL; NITRATION; NONHUMAN; OXIDATION; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; TRANSCYTOSIS; VASCULAR DISEASE; VASODILATATION;

ANIMALS; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; PEROXIDASE; VASCULAR DISEASES;

EID: 33646757884     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2005.06.023     Document Type: Review

References (134)

1. Abu-Soud H.M., and Hazen S.L. Nitric oxide is a physiological substrate for mammalian peroxidases. J Biol Chem 275 (2000) 37524-37532
2. Abu-Soud H.M., and Hazen S.L. Nitric oxide modulates the catalytic activity of myeloperoxidase. J Biol Chem 275 (2000) 5425-5430
3. Akin D.T., and Kinkade Jr. J.M. Processing of a newly identified intermediate of human myeloperoxidase in isolated granules occurs at neutral pH. J Biol Chem 261 (1986) 8370-8375
4. Albertini M., Clement M.G., Lafortuna C.L., Caniatti M., Magder S., Abdulmalek K., et al. Role of poly-(ADP-ribose) synthetase in lipopolysaccharide-induced vascular failure and acute lung injury in pigs. J Crit Care 15 (2000) 73-83
5. Aratani Y., Kura F., Watanabe H., Akagawa H., Takano Y., Suzuki K., et al. Differential host susceptibility to pulmonary infections with bacteria and fungi in mice deficient in myeloperoxidase. J Infect Dis 182 (2000) 1276-1279
6. Arbustini E., Dal Bello B., Morbini P., Burke A.P., Bocciarelli M., Specchia G., et al. Plaque erosion is a major substrate for coronary thrombosis in acute myocardial infarction. Heart 82 (1999) 269-272
7. Arnljots K., and Olsson I. Myeloperoxidase precursors incorporate heme. J Biol Chem 262 (1987) 10430-10433
8. Askari A.T., Brennan M.L., Zhou X., Drinko J., Morehead A., Thomas J.D., et al. Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. J Exp Med 197 (2003) 615-624
9. Asselbergs F.W., Tervaert J.W., and Tio R.A. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 350 (2004) 516-518 [author reply 516-8]
10. Babior B.M. Phagocytes and oxidative stress. Am J Med 109 (2000) 33-44
11. Baldus S., Eiserich J.P., Mani A., Castro L., Figueroa M., Chumley P., et al. Endothelial transcytosis of myeloperoxidase confers specificity to vascular ECM proteins as targets of tyrosine nitration. J Clin Invest 108 (2001) 1759-1770
12. Baldus S., Eiserich J.P., Brennan M.L., Jackson R.M., Alexander C.B., and Freeman B.A. Spatial mapping of pulmonary and vascular nitrotyrosine reveals the pivotal role of myeloperoxidase as a catalyst for tyrosine nitration in inflammatory diseases. Free Radic Biol Med 33 (2002) 1010
13. Baldus S., Heeschen C., Meinertz T., Zeiher A.M., Eiserich J.P., Munzel T., et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 108 (2003) 1440-1445
14. Baldus S., Heitzer T., Eiserich J.P., Lau D., Mollnau H., Ortak M., et al. Myeloperoxidase enhances nitric oxide catabolism during myocardial ischemia and reperfusion. Free Radic Biol Med 37 (2004) 902-911
15. Beckman J.S., and Koppenol W.H. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 271 (1996) C1424-C1437
16. Beckmann J.S., Ye Y.Z., Anderson P.G., Chen J., Accavitti M.A., Tarpey M.M., et al. Extensive nitration of protein tyrosines in human atherosclerosis detected by immunohistochemistry. Biol Chem Hoppe Seyler 375 (1994) 81-88
17. Bergt C., Pennathur S., Fu X., Byun J., O'Brien K., McDonald T.O., et al. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci USA 101 (2004) 13032-13037
18. Bos A., Wever R., and Roos D. Characterization and quantification of the peroxidase in human monocytes. Biochim Biophys Acta 525 (1978) 37-44
19. Brennan M.L., and Hazen S.L. Emerging role of myeloperoxidase and oxidant stress markers in cardiovascular risk assessment. Curr Opin Lipidol 14 (2003) 353-359
20. Brennan M.L., Anderson M.M., Shih D.M., Qu X.D., Wang X., Mehta A.C., et al. Increased atherosclerosis in myeloperoxidase-deficient mice. J Clin Invest 107 (2001) 419-430
21. Brennan M.L., Wu W., Fu X., Shen Z., Song W., Frost H., et al. A tale of two controversies: defining both the role of peroxidases in nitrotyrosine formation in vivo using eosinophil peroxidase and myeloperoxidase-deficient mice, and the nature of peroxidase-generated reactive nitrogen species. J Biol Chem 277 (2002) 17415-17427
22. Brennan M.L., Penn M.S., Van Lente F., Nambi V., Shishehbor M.H., Aviles R.J., et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 349 (2003) 1595-1604
23. Brown K.E., Brunt E.M., and Heinecke J.W. Immunohistochemical detection of myeloperoxidase and its oxidation products in Kupffer cells of human liver. Am J Pathol 159 (2001) 2081-2088
24. Buffon A., Biasucci L.M., Liuzzo G., D'Onofrio G., Crea F., and Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med 347 (2002) 5-12
25. Campbell E.J., Campbell M.A., and Owen C.A. Bioactive proteinase 3 on the cell surface of human neutrophils: quantification, catalytic activity, and susceptibility to inhibition. J Immunol 165 (2000) 3366-3374
26. Cassina A.M., Hodara R., Souza J.M., Thomson L., Castro L., Ischiropoulos H., et al. Cytochrome c nitration by peroxynitrite. J Biol Chem 275 (2000) 21409-21415
27. Daphna E.M., Michaela S., Eynat P., Irit A., and Rimon S. Association of myeloperoxidase with heparin: oxidative inactivation of proteins on the surface of endothelial cells by the bound enzyme. Mol Cell Biochem 183 (1998) 55-61
28. Daugherty A., Dunn J.L., Rateri D.L., and Heinecke J.W. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 94 (1994) 437-444
29. De Caterina R., Libby P., Peng H.B., Thannickal V.J., Rajavashisth T.B., Gimbrone Jr. M.A., et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 96 (1995) 60-68
30. Deby-Dupont G., and Lamy M. Neutrophil myeloperoxidase revisited: it's role in health and disease. Intensivmedizin 36 (1999) 500-513
31. Desrochers P.E., and Weiss S.J. Proteolytic inactivation of alpha-1-proteinase inhibitor by a neutrophil metalloproteinase. J Clin Invest 81 (1988) 1646-1650
32. Doehner W., Schoene N., Rauchhaus M., Leyva-Leon F., Pavitt D.V., Reaveley D.A., et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 105 (2002) 2619-2624
33. Eiserich J.P., Hristova M., Cross C.E., Jones A.D., Freeman B.A., Halliwell B., et al. Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. Nature 391 (1998) 393-397
34. Eiserich J.P., Estevez A.G., Bamberg T.V., Ye Y.Z., Chumley P.H., Beckman J.S., et al. Microtubule dysfunction by posttranslational nitrotyrosination of alpha-tubulin: a nitric oxide-dependent mechanism of cellular injury. Proc Natl Acad Sci USA 96 (1999) 6365-6370
35. Eiserich J.P., Baldus S., Brennan M.L., Ma W., Zhang C., Tousson A., et al. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science 296 (2002) 2391-2394
36. Everse J. The structure of heme proteins compounds I and II: some misconceptions. Free Radic Biol Med 24 (1998) 1338-1346
37. Falk R.J., and Jennette J.C. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med 318 (1988) 1651-1657
38. Falk R.J., Terrell R.S., Charles L.A., and Jennette J.C. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 87 (1990) 4115-4119
39. Farb A., Burke A.P., Tang A.L., Liang T.Y., Mannan P., Smialek J., et al. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation 93 (1996) 1354-1363
40. Farrell A.J., Blake D.R., Palmer R.M., and Moncada S. Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. Ann Rheum Dis 51 (1992) 1219-1222
41. Fenna R., Zeng J., and Davey C. Structure of the green heme in myeloperoxidase. Arch Biochem Biophys 316 (1995) 653-656
42. Fliss H. Oxidation of proteins in rat heart and lungs by polymorphonuclear leukocyte oxidants. Mol Cell Biochem 84 (1988) 177-188
43. Folkes L.K., Candeias L.P., and Wardman P. Kinetics and mechanisms of hypochlorous acid reactions. Arch Biochem Biophys 323 (1995) 120-126
44. Fu X., Kassim S.Y., Parks W.C., and Heinecke J.W. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J Biol Chem 276 (2001) 41279-41287
45. Gaston B., Reilly J., Drazen J.M., Fackler J., Ramdev P., Arnelle D., et al. Endogenous nitrogen oxides and bronchodilator S-nitrosothiols in human airways. Proc Natl Acad Sci USA 90 (1993) 10957-10961
46. George S.J. Tissue inhibitors of metalloproteinases and metalloproteinases in atherosclerosis. Curr Opin Lipidol 9 (1998) 413-423
47. Green P.S., Mendez A.J., Jacob J.S., Crowley J.R., Growdon W., Hyman B.T., et al. Neuronal expression of myeloperoxidase is increased in Alzheimer's disease. J Neurochem 90 (2004) 724-733
48. Hagen E.C., Daha M.R., Hermans J., Andrassy K., Csernok E., Gaskin G., et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int 53 (1998) 743-753
49. Harper L., and Savage C.O. Pathogenesis of ANCA-associated systemic vasculitis. J Pathol 190 (2000) 349-359
50. Hazen S.L. Myeloperoxidase and plaque vulnerability. Arterioscler Thromb Vasc Biol 24 (2004) 1143-1146
51. Hazen S.L., Zhang R., Shen Z., Wu W., Podrez E.A., MacPherson J.C., et al. Formation of nitric oxide-derived oxidants by myeloperoxidase in monocytes: pathways for monocyte-mediated protein nitration and lipid peroxidation In vivo. Circ Res 85 (1999) 950-958
52. Hickman-Davis J.M., Lindsey J.R., and Matalon S. Cyclophosphamide decreases nitrotyrosine formation and inhibits nitric oxide production by alveolar macrophages in mycoplasmosis. Infect Immun 69 (2001) 6401-6410
53. Hirabayashi H., Takizawa S., Fukuyama N., Nakazawa H., and Shinohara Y. Nitrotyrosine generation via inducible nitric oxide synthase in vascular wall in focal ischemia-reperfusion. Brain Res 852 (2000) 319-325
54. Hori K., Burd P.R., Furuke K., Kutza J., Weih K.A., and Clouse K.A. Human immunodeficiency virus-1-infected macrophages induce inducible nitric oxide synthase and nitric oxide (NO) production in astrocytes: astrocytic NO as a possible mediator of neural damage in acquired immunodeficiency syndrome. Blood 93 (1999) 1843-1850
55. Hoy A., Tregouet D., Leininger-Muller B., Poirier O., Maurice M., Sass C., et al. Serum myeloperoxidase concentration in a healthy population: biological variations, familial resemblance and new genetic polymorphisms. Eur J Hum Genet 9 (2001) 780-786
56. Hurst J.K., and Barrette Jr. W.C. Leukocytic oxygen activation and microbicidal oxidative toxins. Crit Rev Biochem Mol Biol 24 (1989) 271-328
57. Ischiropoulos H. Biological tyrosine nitration: a pathophysiological function of nitric oxide and reactive oxygen species. Arch Biochem Biophys 356 (1998) 1-11
58. Ishibashi S., Brown M.S., Goldstein J.L., Gerard R.D., Hammer R.E., and Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 92 (1993) 883-893
59. Jandl R.C., Andre-Schwartz J., Borges-DuBois L., Kipnes R.S., McMurrich B.J., and Babior B.M. Termination of the respiratory burst in human neutrophils. J Clin Invest 61 (1978) 1176-1185
60. Jiang Q., and Hurst J.K. Relative chlorinating, nitrating, and oxidizing capabilities of neutrophils determined with phagocytosable probes. J Biol Chem 272 (1997) 32767-32772
61. Kawano S., Tatsumi E., Yoneda N., Nagata S., and Yamaguchi N. Suppression of gene expression of myeloperoxidase (MPO) by gamma-interferon (IFN-gamma) in HL60 cells. Lymphokine Cytokine Res 12 (1993) 81-85
62. Kettle A.J., van Dalen C.J., and Winterbourn C.C. Peroxynitrite and myeloperoxidase leave the same footprint in protein nitration. Redox Rep 3 (1997) 257-258
63. Klebanoff S.J. Myeloperoxidase. Proc Assoc Am Physicians 111 (1999) 383-389
64. Klebanoff S.J., Waltersdorph A.M., and Rosen H. Antimicrobial activity of myeloperoxidase. Methods Enzymol 105 (1984) 399-403
65. Kobayashi S.D., Voyich J.M., Buhl C.L., Stahl R.M., and DeLeo F.R. Global changes in gene expression by human polymorphonuclear leukocytes during receptor-mediated phagocytosis: cell fate is regulated at the level of gene expression. Proc Natl Acad Sci USA 99 (2002) 6901-6906
66. Koeffler H.P., Ranyard J., and Pertcheck M. Myeloperoxidase: its structure and expression during myeloid differentiation. Blood 65 (1985) 484-491
67. Kooy N.W., Lewis S.J., Royall J.A., Ye Y.Z., Kelly D.R., and Beckman J.S. Extensive tyrosine nitration in human myocardial inflammation: evidence for the presence of peroxynitrite. Crit Care Med 25 (1997) 812-819
68. Kutter D., Devaquet P., Vanderstocken G., Paulus J.M., Marchal V., and Gothot A. Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit?. Acta Haematol 104 (2000) 10-15
69. Lamb N.J., Gutteridge J.M., Baker C., Evans T.W., and Quinlan G.J. Oxidative damage to proteins of bronchoalveolar lavage fluid in patients with acute respiratory distress syndrome: evidence for neutrophil-mediated hydroxylation, nitration, and chlorination. Crit Care Med 27 (1999) 1738-1744
70. Landmesser U., Spiekermann S., Dikalov S., Tatge H., Wilke R., Kohler C., et al. Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation 106 (2002) 3073-3078
71. Lau D., Mollnau H., Eiserich J.P., Freeman B.A., Daiber A., Gehling U.M., et al. Myeloperoxidase mediates neutrophil activation by association with CD11b/CD18 integrins. Proc Natl Acad Sci USA 102 (2005) 431-436
72. Leeuwenburgh C., Hardy M.M., Hazen S.L., Wagner P., Oh-ishi S., Steinbrecher U.P., et al. Reactive nitrogen intermediates promote low density lipoprotein oxidation in human atherosclerotic intima. J Biol Chem 272 (1997) 1433-1436
73. Leeuwenburgh C., Rasmussen J.E., Hsu F.F., Mueller D.M., Pennathur S., and Heinecke J.W. Mass spectrometric quantification of markers for protein oxidation by tyrosyl radical, copper, and hydroxyl radical in low density lipoprotein isolated from human atherosclerotic plaques. J Biol Chem 272 (1997) 3520-3526
74. Libby P. Molecular bases of the acute coronary syndromes. Circulation 91 (1995) 2844-2850
75. Libby P. Coronary artery injury and the biology of atherosclerosis: inflammation, thrombosis, and stabilization. Am J Cardiol 86 (2000) 3J-8J (discussion 8J-9J)
76. Locksley R.M., Nelson C.S., Fankhauser J.E., and Klebanoff S.J. Loss of granule myeloperoxidase during in vitro culture of human monocytes correlates with decay in antiprotozoa activity. Am J Trop Med Hyg 36 (1987) 541-548
77. MacMillan-Crow L.A., Crow J.P., Kerby J.D., Beckman J.S., and Thompson J.A. Nitration and inactivation of manganese superoxide dismutase in chronic rejection of human renal allografts. Proc Natl Acad Sci USA 93 (1996) 11853-11858
78. Magnusson M.K., and Mosher D.F. Fibronectin: structure, assembly, and cardiovascular implications. Arterioscler Thromb Vasc Biol 18 (1998) 1363-1370
79. 2/halide system in human atherosclerotic lesions: colocalization of myeloperoxidase and hypochlorite-modified proteins. Eur J Biochem 267 (2000) 4495-4503
80. Marquez L.A., and Dunford H.B. Reaction of compound III of myeloperoxidase with ascorbic acid. J Biol Chem 265 (1990) 6074-6078
81. Marquez L.A., Dunford H.B., and Van Wart H. Kinetic studies on the reaction of compound II of myeloperoxidase with ascorbic acid. Role of ascorbic acid in myeloperoxidase function. J Biol Chem 265 (1990) 5666-5670
82. Marquez L.A., Huang J.T., and Dunford H.B. Spectral and kinetic studies on the formation of myeloperoxidase compounds I and II: roles of hydrogen peroxide and superoxide. Biochemistry 33 (1994) 1447-1454
83. Marsche G., Heller R., Fauler G., Kovacevic A., Nuszkowski A., Graier W., et al. 2-chlorohexadecanal derived from hypochlorite-modified high-density lipoprotein-associated plasmalogen is a natural inhibitor of endothelial nitric oxide biosynthesis. Arterioscler Thromb Vasc Biol 24 (2004) 2302-2306
84. Middleton J., Neil S., Wintle J., Clark-Lewis I., Moore H., Lam C., et al. Transcytosis and surface presentation of IL-8 by venular endothelial cells. Cell 91 (1997) 385-395
85. Midwinter R.G., Vissers M.C., and Winterbourn C.C. Hypochlorous acid stimulation of the mitogen-activated protein kinase pathway enhances cell survival. Arch Biochem Biophys 394 (2001) 13-20
86. Mohacsi A., Kozlovszky B., Kiss I., Seres I., and Fulop Jr. T. Neutrophils obtained from obliterative atherosclerotic patients exhibit enhanced resting respiratory burst and increased degranulation in response to various stimuli. Biochim Biophys Acta 1316 (1996) 210-216
87. Nagra R.M., Becher B., Tourtellotte W.W., Antel J.P., Gold D., Paladino T., et al. Immunohistochemical and genetic evidence of myeloperoxidase involvement in multiple sclerosis. J Neuroimmunol 78 (1997) 97-107
88. Nakagawara A., Nathan C.F., and Cohn Z.A. Hydrogen peroxide metabolism in human monocytes during differentiation in vitro. J Clin Invest 68 (1981) 1243-1252
89. Nauseef W.M. Myeloperoxidase deficiency. Hematol Oncol Clin North Am 2 (1988) 135-158
90. Nauseef W.M. Insights into myeloperoxidase biosynthesis from its inherited deficiency. J Mol Med 76 (1998) 661-668
91. Nauseef W.M., Metcalf J.A., and Root R.K. Role of myeloperoxidase in the respiratory burst of human neutrophils. Blood 61 (1983) 483-492
92. Nikpoor B., Turecki G., Fournier C., Theroux P., and Rouleau G.A. A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am Heart J 142 (2001) 336-339
93. Noguchi N., Nakano K., Aratani Y., Koyama H., Kodama T., and Niki E. Role of myeloperoxidase in the neutrophil-induced oxidation of low density lipoprotein as studied by myeloperoxidase-knockout mouse. J Biochem (Tokyo) 127 (2000) 971-976
94. Obunike J.C., Lutz E.P., Li Z., Paka L., Katopodis T., Strickland D.K., et al. Transcytosis of lipoprotein lipase across cultured endothelial cells requires both heparan sulfate proteoglycans and the very low density lipoprotein receptor. J Biol Chem 276 (2001) 8934-8941
95. Pecoits-Filho R., Stenvinkel P., Marchlewska A., Heimburger O., Barany P., Hoff C.M., et al. A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. Kidney Int Suppl (2003) S172-S176
96. Pennathur S., Bergt C., Shao B., Byun J., Kassim S.Y., Singh P., et al. Human atherosclerotic intima and blood of patients with established coronary artery disease contain high density lipoprotein damaged by reactive nitrogen species. J Biol Chem (2004)
97. Radford D.J., Luu N.T., Hewins P., Nash G.B., and Savage C.O. Anti-neutrophil cytoplasmic antibodies stabilize adhesion and promote migration of flowing neutrophils on endothelial cells. Arthritis Rheum 44 (2001) 2851-2861
98. Rarok A.A., Limburg P.C., and Kallenberg C.G. Neutrophil-activating potential of antineutrophil cytoplasm autoantibodies. J Leukoc Biol 74 (2003) 3-15
99. Rausch P.G., and Moore T.G. Granule enzymes of polymorphonuclear neutrophils: a phylogenetic comparison. Blood 46 (1975) 913-919
100. Retnoningrum D.S., and Cleary P.P. M12 protein from Streptococcus pyogenes is a receptor for immunoglobulin G3 and human albumin. Infect Immun 62 (1994) 2387-2394
101. Reumaux D., Vossebeld P.J., Roos D., and Verhoeven A.J. Effect of tumor necrosis factor-induced integrin activation on Fc gamma receptor II-mediated signal transduction: relevance for activation of neutrophils by anti-proteinase 3 or anti-myeloperoxidase antibodies. Blood 86 (1995) 3189-3195
102. Salvemini D., Currie M.G., and Mollace V. Nitric oxide-mediated cyclooxygenase activation. A key event in the antiplatelet effects of nitrovasodilators. J Clin Invest 97 (1996) 2562-2568
103. Sato E., Koyama S., Camhi S.L., Nelson D.K., and Robbins R.A. Reactive oxygen and nitrogen metabolites modulate fibronectin-induced fibroblast migration in vitro. Free Radic Biol Med 30 (2001) 22-29
104. Schmitt D., Shen Z., Zhang R., Colles S.M., Wu W., Salomon R.G., et al. Leukocytes utilize myeloperoxidase-generated nitrating intermediates as physiological catalysts for the generation of biologically active oxidized lipids and sterols in serum. Biochemistry 38 (1999) 16904-16915
105. Schopfer F.J., Baker P.R., and Freeman B.A. NO-dependent protein nitration: a cell signaling event or an oxidative inflammatory response?. Trends Biochem Sci 28 (2003) 646-654
106. Shabani F., McNeil J., and Tippett L. The oxidative inactivation of tissue inhibitor of metalloproteinase-1 (TIMP-1) by hypochlorous acid (HOCI) is suppressed by anti-rheumatic drugs. Free Radic Res 28 (1998) 115-123
107. Shishehbor M.H., Aviles R.J., Brennan M.L., Fu X., Goormastic M., Pearce G.L., et al. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. Jama 289 (2003) 1675-1680
108. Spiekermann S., Landmesser U., Dikalov S., Bredt M., Gamez G., Tatge H., et al. Electron spin resonance characterization of vascular xanthine and NAD(P)H oxidase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation 107 (2003) 1383-1389
109. Taylor K.L., Guzman G.S., Burgess C.A., and Kinkade Jr. J.M. Assembly of dimeric myeloperoxidase during posttranslational maturation in human leukemic HL-60 cells. Biochemistry 29 (1990) 1533-1539
110. Taylor K.L., Strobel F., Yue K.T., Ram P., Pohl J., Woods A.S., et al. Isolation and identification of a protoheme IX derivative released during autolytic cleavage of human myeloperoxidase. Arch Biochem Biophys 316 (1995) 635-642
111. Than T.A., Ogino T., Hosako M., Omori M., Tsuchiyama J., and Okada S. Physiological oxidants induce apoptosis and cell cycle arrest in a multidrug-resistant natural killer cell line, NK-YS. Leuk Lymphoma 44 (2003) 2109-2116
112. Tiruppathi C., Naqvi T., Wu Y., Vogel S.M., Minshall R.D., and Malik A.B. Albumin mediates the transcytosis of myeloperoxidase by means of caveolae in endothelial cells. Proc Natl Acad Sci USA 101 (2004) 7699-7704
113. Tobler A., Miller C.W., Johnson K.R., Selsted M.E., Rovera G., and Koeffler H.P. Regulation of gene expression of myeloperoxidase during myeloid differentiation. J Cell Physiol 136 (1988) 215-225
114. Torre D., Ferrario G., Speranza F., Orani A., Fiori G.P., and Zeroli C. Serum concentrations of nitrite in patients with HIV-1 infection. J Clin Pathol 49 (1996) 574-576
115. Vadseth C., Souza J.M., Thomson L., Seagraves A., Nagaswami C., Scheiner T., et al. Pro-thrombotic State Induced by Post-translational Modification of Fibrinogen by Reactive Nitrogen Species. J Biol Chem 279 (2004) 8820-8826
116. van Dalen C.J., Whitehouse M.W., Winterbourn C.C., and Kettle A.J. Thiocyanate and chloride as competing substrates for myeloperoxidase. Biochem J 327 Pt. 2 (1997) 487-492
117. van der Vliet A., Eiserich J.P., Halliwell B., and Cross C.E. Formation of reactive nitrogen species during peroxidase-catalyzed oxidation of nitrite. A potential additional mechanism of nitric oxide-dependent toxicity. J Biol Chem 272 (1997) 7617-7625
118. Van Der Vliet A., Nguyen M.N., Shigenaga M.K., Eiserich J.P., Marelich G.P., and Cross C.E. Myeloperoxidase and protein oxidation in cystic fibrosis. Am J Physiol Lung Cell Mol Physiol 279 (2000) L537-L546
119. Vercellotti G.M., McCarthy J., Furcht L.T., Jacob H.S., and Moldow C.F. Inflamed fibronectin: an altered fibronectin enhances neutrophil adhesion. Blood 62 (1983) 1063-1069
120. Vile G.F., Rothwell L.A., and Kettle A.J. Hypochlorous acid activates the tumor suppressor protein p53 in cultured human skin fibroblasts. Arch Biochem Biophys 359 (1998) 51-56
121. Viner R.I., Ferrington D.A., Williams T.D., Bigelow D.J., and Schoneich C. Protein modification during biological aging: selective tyrosine nitration of the SERCA2a isoform of the sarcoplasmic reticulum Ca2+-ATPase in skeletal muscle. Biochem J 340 Pt 3 (1999) 657-669
122. Vissers M.C., and Thomas C. Hypochlorous acid disrupts the adhesive properties of subendothelial matrix. Free Radic Biol Med 23 (1997) 401-411
123. Wever R., and Plat H. Spectral properties of myeloperoxidase and its ligand complexes. Biochim Biophys Acta 661 (1981) 235-239
124. Whitman S.C., Hazen S.L., Miller D.B., Hegele R.A., Heinecke J.W., and Huff M.W. Modification of type III VLDL, their remnants, and VLDL from ApoE-knockout mice by p-hydroxyphenylacetaldehyde, a product of myeloperoxidase activity, causes marked cholesteryl ester accumulation in macrophages. Arterioscler Thromb Vasc Biol 19 (1999) 1238-1249
125. Winterbourn C.C. Comparative reactivities of various biological compounds with myeloperoxidase-hydrogen peroxide-chloride, and similarity of the oxidant to hypochlorite. Biochim Biophys Acta 840 (1985) 204-210
126. Winterbourn C.C., Vissers M.C., and Kettle A.J. Myeloperoxidase. Curr Opin Hematol 7 (2000) 53-58
127. Wu W., Chen Y., and Hazen S.L. Eosinophil peroxidase nitrates protein tyrosyl residues. Implications for oxidative damage by nitrating intermediates in eosinophilic inflammatory disorders. J Biol Chem 274 (1999) 25933-25944
128. Zeng J., and Fenna R.E. X-ray crystal structure of canine myeloperoxidase at 3 A resolution. J Mol Biol 226 (1992) 185-207
129. Zhang C., Reiter C., Eiserich J.P., Boersma B., Parks D.A., Beckman J.S., et al. l-Arginine chlorination products inhibit endothelial nitric oxide production. J Biol Chem 276 (2001) 27159-27165
130. Zhang R., Brennan M.L., Fu X., Aviles R.J., Pearce G.L., Penn M.S., et al. Association between myeloperoxidase levels and risk of coronary artery disease. Jama 286 (2001) 2136-2142
131. Zhang R., Brennan M.L., Shen Z., MacPherson J.C., Schmitt D., Molenda C.E., et al. Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation. J Biol Chem 277 (2002) 46116-46122
132. Zhang C., Yang J., Jacobs J.D., and Jennings L.K. Interaction of myeloperoxidase with vascular NAD(P)H oxidase-derived reactive oxygen species in vasculature: implications for vascular diseases. Am J Physiol Heart Circ Physiol 285 (2003) H2563-H2572
133. Zhao W.G., Regmi A., Austin E.D., Braun J.E., Racine M., and Austin G.E. Cis-elements in the promoter region of the human myeloperoxidase (MPO) gene. Leukemia 10 (1996) 1089-1103
134. Zheng L., Nukuna B., Brennan M.L., Sun M., Goormastic M., Settle M., et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 114 (2004) 529-541